- Home
- JANX vs TVTX Comparison
JANX vs TVTX Comparison
Compare JANX & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- TVTX
- Stock Information
- Founded
- JANX 2017
- TVTX 2008
- Country
- JANX United States
- TVTX United States
- Employees
- JANX N/A
- TVTX N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- TVTX Health Care
- Exchange
- JANX Nasdaq
- TVTX Nasdaq
- Market Cap
- JANX 2.2B
- TVTX 1.8B
- IPO Year
- JANX 2021
- TVTX N/A
- Fundamental
- Price
- JANX $36.01
- TVTX $21.98
- Analyst Decision
- JANX Strong Buy
- TVTX Strong Buy
- Analyst Count
- JANX 11
- TVTX 12
- Target Price
- JANX $83.09
- TVTX $30.08
- AVG Volume (30 Days)
- JANX 821.6K
- TVTX 1.8M
- Earning Date
- JANX 03-07-2025
- TVTX 02-20-2025
- Dividend Yield
- JANX N/A
- TVTX N/A
- EPS Growth
- JANX N/A
- TVTX N/A
- EPS
- JANX N/A
- TVTX N/A
- Revenue
- JANX $13,049,000.00
- TVTX $233,175,000.00
- Revenue This Year
- JANX $39.66
- TVTX $62.88
- Revenue Next Year
- JANX N/A
- TVTX $57.60
- P/E Ratio
- JANX N/A
- TVTX N/A
- Revenue Growth
- JANX 54.12
- TVTX 60.55
- 52 Week Low
- JANX $14.68
- TVTX $5.12
- 52 Week High
- JANX $71.71
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- JANX 34.78
- TVTX 53.52
- Support Level
- JANX $36.13
- TVTX $22.48
- Resistance Level
- JANX $38.13
- TVTX $23.69
- Average True Range (ATR)
- JANX 2.52
- TVTX 1.22
- MACD
- JANX 0.08
- TVTX -0.02
- Stochastic Oscillator
- JANX 5.71
- TVTX 41.10
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.